Divi's Labs

Strong custom synthesis growth, improving margins and projects nearing commercialisation support Divi's Labs' outlook, though elevated valuations remain a concern for analysts

Updated On: 09 Nov 2026 | 10:05 PM IST

Divi's Laboratories Ltd on Saturday posted a sharp 63.57 per cent rise in net profit to Rs 1,127 crore in the September quarter due to higher revenues. The company posted a net profit of Rs 689 crore in the corresponding period of the previous fiscal year, a regulatory filing said. Revenue from operations rose 35.39 per cent to Rs 3,676 crore during the second quarter of FY27 from Rs 2,715 crore a year earlier, it said. Its total expenses rose to Rs 2,265 crore in the period under review from Rs 1,948 crore a year ago, it added. The company's net profit for the first half of the current fiscal year, however, declined 35.39 per cent to Rs 2,029 crore from Rs 2,568 crore in the year-ago period, the filing added.

Updated On: 07 Nov 2026 | 3:11 PM IST

Q1FY27 company results: Firms including Aarti Surfactants, Aditya Birla Lifestyle Brands, APL Apollo Tubes, and Utkarsh Small Finance Bank are also to release their April-June earnings today

Updated On: 01 Aug 2026 | 8:16 AM IST

Divi's Laboratories MD Murali K Divi topped India's pharma executive pay chart in FY26 with ₹100.26 crore, driven almost entirely by profit-linked commission

Updated On: 20 Jul 2026 | 12:05 AM IST

The Hyderabad-based company's consolidated net profit marginally fell to ₹583 crore ($64.31 million) in the quarter ended December 31, from ₹589 crore a year earlier

Updated On: 11 Feb 2026 | 2:46 PM IST

While HDFC Securities has assigned a 'Buy' rating to Divi's Labs, Sai Life Sciences, and Piramal Pharma, it has given an 'Add' rating to Anthem BioSciences and a 'Reduce' rating to Laurus Labs

Updated On: 09 Jan 2026 | 11:41 AM IST

Despite strong custom synthesis growth and better-than-expected quarterly results, analysts caution that high valuations could restrict near-term gains for Divi's Laboratories

Updated On: 11 Nov 2025 | 10:35 PM IST

Divis stock gained 2% in Monday's intra-day deals. Reports suggest the company is well positioned to benefit from emerging trends across both API and CDMO domains through innovation and capex.

Updated On: 13 Oct 2025 | 11:23 AM IST

Divi's Laboratories reported a 14 per cent year-on-year jump in revenue at ₹2,410 crore in Q1FY26, compared to ₹2,118 crore in the year-ago period

Updated On: 07 Aug 2025 | 1:41 PM IST

The recent price action in the Nifty indicates that the bulls are making a strong effort to sustain the prevailing uptrend. Buy GAIL, Tata Steel and this one stock today

Updated On: 22 May 2025 | 7:24 AM IST

Drug firm Divi's Laboratories on Monday said its profit after tax (PAT) increased 65 per cent to Rs 589 crore for the December quarter, on the back of robust sales across markets. The company had reported a profit after tax (PAT) of Rs 358 crore for the October-December quarter of last fiscal. Revenue from operations rose to Rs 2,319 crore in the third quarter as against Rs 1,855 crore in the year-ago period, Divi's Laboratories said in a regulatory filing. The drug firm noted a part of the Kakinada Project (Unit-III) commenced commercial operations from January 1, 2025. The rest of Kakinada project is being implemented and is expected to be operational in about six months, it added. "We have capitalised assets of Rs 433 crore for the quarter and of Rs 557 crore for the nine-month period of the current fiscal year. Of this, capitalisation for Kakinada Project is Rs 418 crore during the 9-month period," the drug firm stated. The company said its board has approved the re-appointme

Updated On: 03 Feb 2025 | 4:18 PM IST

Its revenue from operations climbed 25 per cent to Rs 2,319 crore during the quarter, roughly in line with analysts' estimate of Rs 2,343 crore

Updated On: 03 Feb 2025 | 2:34 PM IST

The company delivered a strong revenue and operating performance in the March quarter

Updated On: 27 May 2024 | 10:13 PM IST

According to the brokerage, prices of APIs such as Paracetamol, Azithromycin, Montelukast, and Meropenem, have all declined in the range of 10-30 per cent over the last one year

Updated On: 02 May 2024 | 12:26 PM IST

As per an affidavit filed with the Election Commission of India, Rahul Gandhi's top stock holdings include Pidilite Industries, Bajaj Finance, Nestle, ITC, Hindustan Unilever and Tube Investments.

Updated On: 08 Apr 2024 | 12:08 PM IST

Motilal Oswal Research is factoring in 25 per cent net profit growth annually over the FY23-25 period adjusting for Covid-led business in FY23

Updated On: 09 Nov 2023 | 9:49 PM IST

Divi's Labs Q2 result: The revenue from operations, however, rose 3 per cent to Rs 1,909 crore in the period from Rs 1,855 crore last year

Updated On: 06 Nov 2023 | 1:35 PM IST

Revenue of the contract research and manufacturing services player was down 21 per cent y-o-y

Updated On: 18 Aug 2023 | 9:52 PM IST

Analysts' average price target of Rs 3,862, however, indicates significant upside. The near-term trend remains bearish

Updated On: 04 Feb 2023 | 12:21 AM IST

EBITDA margins declined 767 bps YoY to 33.5 per cent due to high energy and transport costs.

Updated On: 09 Nov 2022 | 9:56 AM IST